Beone Medicines USA Inc v. Zydus Pharma USA Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: BeOne Medicines USA, Inc. (Delaware) and BeOne Medicines I GmbH (Switzerland)
  • Defendant: Zydus Pharmaceuticals (USA) Inc. (New Jersey) and Zydus Lifesciences Limited (India)
  • Plaintiff's Counsel: Walsh Pizzi O'Reilly Falanga LLP; Williams & Connolly LLP
• Case Identification: 2:26-cv-02010, D.N.J., 02/25/2026
• Venue Allegations: Venue is alleged as proper in the District of New Jersey on the basis that Defendant Zydus USA maintains its principal place of business in the district and has committed or will commit acts of infringement there. Venue is asserted over Zydus Lifesciences as a foreign corporation subject to personal jurisdiction in the district.
• Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the cancer drug BRUKINSA® (zanubrutinib) constitutes an act of infringement of ten U.S. patents covering the drug's specific crystalline form, methods of its use for treating various cancers, and its tablet formulation.
• Technical Context: The technology relates to pharmaceutical chemistry, specifically a stable crystalline polymorph of zanubrutinib, a Bruton's Tyrosine Kinase (BTK) inhibitor used in the treatment of B-cell cancers.
• Key Procedural History: The action arises from a notice letter dated January 19, 2026, in which Zydus informed Plaintiffs of its ANDA submission containing Paragraph IV certifications. These certifications allege that the patents-in-suit are invalid and/or will not be infringed by Zydus's proposed generic product, thereby triggering this Hatch-Waxman patent infringement lawsuit.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,927,117 - "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof"

• Patent Identification: U.S. Patent No. 10,927,117, "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof," issued February 23, 2021 Compl. ¶ 40
• The Invention Explained:
  • Problem Addressed: The patent specification describes the amorphous form of the active pharmaceutical ingredient, zanubrutinib (referred to as Compound 1), as having deficiencies such as "low stability and hard to purify," which create "difficulties in the drug formulation" '117 Patent, col. 2:62-67
  • The Patented Solution: The patent discloses and claims a specific, stable crystalline form of zanubrutinib, designated "Crystalline Form A" '117 Patent, col. 3:1-5 This form is defined by characteristic peaks in its X-ray powder diffraction (XRPD) pattern and is described as having a high melting point and a stable profile, making it suitable for drug formulation '117 Patent, col. 3:8-12 '117 Patent, abstract
  • Technical Importance: Developing a stable, pure crystalline form of a drug is a critical step in pharmaceutical manufacturing, as it ensures product consistency, stability, and predictable bioavailability, which are significant advantages over a less stable amorphous form '117 Patent, col. 2:62-67
• Key Claims at a Glance:
  • The complaint asserts independent claim 1 Compl. ¶ 48 and notes infringement of claims 1 through 6 Compl. ¶ 57
  • The essential elements of independent claim 1 are:
    • A crystalline form of Compound 1,
    • wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 15.6±0.2°, 16.4±0.2° and 21.4±0.2°.
  • The complaint does not explicitly reserve the right to assert other dependent claims but alleges infringement of claims 1 through 6 Compl. ¶ 57

U.S. Patent No. 11,591,340 - "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof"

• Patent Identification: U.S. Patent No. 11,591,340, "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof," issued February 28, 2023 Compl. ¶ 72
• The Invention Explained:
  • Problem Addressed: The patent background, identical to that of the '117 patent, notes the formulation and stability challenges associated with the amorphous form of zanubrutinib '340 Patent, col. 2:62-67
  • The Patented Solution: The patent claims methods of using the specific crystalline form of zanubrutinib-defined by the same characteristic XRPD peaks as in the '117 patent-to treat specific B-cell cancers, including mantle cell lymphoma '340 Patent, claim 1 The patent thus covers the therapeutic application of this particular solid-state form of the drug.
  • Technical Importance: Claiming a method of treatment using a specific, stable crystalline form provides a layer of protection that connects the physical form of the drug substance to its therapeutic use, which is important for ensuring consistent clinical efficacy '340 Patent, claim 1
• Key Claims at a Glance:
  • The complaint asserts independent claims 1, 8, 14, and 21 (Compl. ¶¶80, 82, 84, 86) and alleges infringement of claims 1 through 27 Compl. ¶ 89
  • The essential elements of independent claim 1 are:
    • A method for treating mantle cell lymphoma in a subject,
    • comprising administering to the subject in need thereof a crystalline form of Compound 1,
    • wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 15.6±0.2°, 16.4±0.2° and 21.4±0.2°.
  • The complaint does not explicitly reserve the right to assert other dependent claims but alleges infringement of a broader range of claims Compl. ¶ 89

U.S. Patent No. 11,851,437 - "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof"

• Patent Identification: U.S. Patent No. 11,851,437, "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof," issued December 26, 2023 Compl. ¶ 104
• Technology Synopsis: This patent claims "Crystalline Form A" of zanubrutinib, defined not only by its XRPD peaks but also by its stability under various storage conditions (e.g., high temperature and humidity) and its method of preparation from an amorphous form '437 Patent, claim 1 '437 Patent, claim 11 This provides an alternative definition of the same crystalline form, focusing on its physical properties and process of creation.
• Asserted Claims: Independent claims 1 and 11 are cited as examples Compl. ¶ 112 Compl. ¶ 114; claims 1-7, 10-16, and 19 are noted as uncontested on infringement grounds, while claims 8-9, 17-18, and 20-29 are also alleged as infringed Compl. ¶¶116-118
• Accused Features: The Zydus ANDA Product is alleged to contain the Crystalline Form A of Compound 1 as recited in the claims Compl. ¶ 113 Compl. ¶ 115

U.S. Patent No. 11,884,674 - "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof"

• Patent Identification: U.S. Patent No. 11,884,674, "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof," issued January 30, 2024 Compl. ¶ 133
• Technology Synopsis: This patent claims a method for treating specific B-cell proliferative diseases by administering zanubrutinib (Compound 1) at a specific dose of 160 mg twice a day (BID). The claims tie a particular dosing regimen to the treatment of a defined set of cancers.
• Asserted Claims: Independent claim 1 is cited as an example Compl. ¶ 141; claims 1-11, 13-20, and 28 are noted as uncontested on infringement grounds, while claims 12 and 21-27 are also alleged as infringed Compl. ¶¶143-145
• Accused Features: The use of Zydus's ANDA Product in accordance with its proposed labeling is alleged to infringe by directing the administration of Compound 1 at the claimed 160 mg BID dose for treating the specified diseases Compl. ¶ 142

U.S. Patent No. 11,970,500 - "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof"

• Patent Identification: U.S. Patent No. 11,970,500, "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof," issued April 30, 2024 Compl. ¶ 160
• Technology Synopsis: This patent claims a method for treating specific B-cell proliferative diseases by administering zanubrutinib (Compound 1) at a specific dose of 320 mg once a day (QD). This is parallel to the '674 patent but covers an alternative, once-daily dosing regimen.
• Asserted Claims: Independent claim 1 is cited as an example Compl. ¶ 168; claims 1-11, 13-20, and 28 are noted as uncontested on infringement grounds, while claims 12 and 21-27 are also alleged as infringed Compl. ¶¶170-172
• Accused Features: The use of Zydus's ANDA Product in accordance with its proposed labeling is alleged to infringe by directing the administration of Compound 1 at the claimed 320 mg QD dose for the specified diseases Compl. ¶ 169

U.S. Patent No. 11,701,357 - "Treatment of B cell cancers using a combination comprising BTK inhibitors"

• Patent Identification: U.S. Patent No. 11,701,357, "Treatment of B cell cancers using a combination comprising BTK inhibitors," issued July 18, 2023 Compl. ¶ 187
• Technology Synopsis: This patent claims a method for delaying the progression or treating B-cell cancer by administering zanubrutinib in combination with another cancer drug, obinutuzumab. The claims specify the dosing amounts and schedules for both drugs.
• Asserted Claims: Independent claim 1 is cited as an example Compl. ¶ 195; claims 1-3, 5, 7, and 9-19 are also alleged as infringed Compl. ¶ 197
• Accused Features: The use of Zydus's ANDA Product as directed by its proposed labeling is alleged to infringe by instructing the claimed combination therapy regimen Compl. ¶ 196

U.S. Patent No. 11,786,531 - "Methods of treating B-cell proliferative disorder"

• Patent Identification: U.S. Patent No. 11,786,531, "Methods of treating B-cell proliferative disorder," issued October 17, 2023 Compl. ¶ 212
• Technology Synopsis: This patent claims a method of treating a B-cell proliferative disorder in a patient who is also receiving a moderate CYP3A inducer, a type of drug that can affect how other drugs are metabolized. The claimed method requires administering zanubrutinib at an adjusted total daily dose of about 640 mg.
• Asserted Claims: Independent claims 1, 11, and 21 are cited as examples (Compl. ¶¶220, 222, 224); claims 1-30 are alleged as infringed Compl. ¶ 227
• Accused Features: The use of Zydus's ANDA Product according to its proposed labeling is alleged to infringe by instructing the administration of zanubrutinib at the adjusted high dose in patients taking a moderate CYP3A inducer Compl. ¶ 221 Compl. ¶ 223 Compl. ¶ 225

U.S. Patent No. 11,896,596 - "Methods of treating B-cell proliferative disorder"

• Patent Identification: U.S. Patent No. 11,896,596, "Methods of treating B-cell proliferative disorder," issued February 13, 2024 Compl. ¶ 242
• Technology Synopsis: This patent claims a method of treating a B-cell disorder in a patient receiving a moderate CYP3A inducer, where the method involves administering zanubrutinib at a dose of about 320 mg twice a day. The claims also specify a list of exemplary moderate CYP3A inducers.
• Asserted Claims: Independent claims 1, 9, and 18 are cited as examples (Compl. ¶¶250, 252, 254); claims 1-26 are alleged as infringed Compl. ¶ 257
• Accused Features: The use of Zydus's ANDA Product according to its proposed labeling is alleged to infringe by directing the administration of zanubrutinib at the claimed dose in patients receiving a moderate CYP3A inducer Compl. ¶ 251 Compl. ¶ 253 Compl. ¶ 255

U.S. Patent No. 11,911,386 - "Methods of treating B-cell proliferative disorder"

• Patent Identification: U.S. Patent No. 11,911,386, "Methods of treating B-cell proliferative disorder," issued February 27, 2024 Compl. ¶ 272
• Technology Synopsis: This patent claims a method of treating a B-cell disorder in a patient "characterized by being administered with a moderate CYP3A inducer," comprising administering zanubrutinib at a total daily dose of about 640 mg. This patent focuses on the patient characteristic rather than just the co-administration.
• Asserted Claims: Independent claims 1, 11, and 21 are cited as examples (Compl. ¶¶280, 282, 284); claims 1-11, 13-21, and 23-30 are alleged as infringed Compl. ¶ 287
• Accused Features: The use of Zydus's ANDA Product according to its proposed labeling is alleged to infringe by directing the administration of zanubrutinib at the adjusted high dose in patients characterized by receiving a moderate CYP3A inducer Compl. ¶ 281 Compl. ¶ 283 Compl. ¶ 285

U.S. Patent No. 12,233,069 - "Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor"

• Patent Identification: U.S. Patent No. 12,233,069, "Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor," issued February 25, 2025 Compl. ¶ 302
• Technology Synopsis: This patent claims a specific solid tablet formulation of zanubrutinib. The claims recite specific ingredients (micronized zanubrutinib in crystal form A, lactose as a filler, a specific glidant) and their relative amounts, as well as a required dissolution profile.
• Asserted Claims: Independent claims 1 and 17 are cited as examples Compl. ¶ 310 Compl. ¶ 312; claims 1-23 are alleged as infringed Compl. ¶ 314
• Accused Features: Zydus's ANDA Product is alleged to be a solid tablet comprising the elements recited in the claims, including the specified excipients and dissolution properties Compl. ¶ 311 Compl. ¶ 313

III. The Accused Instrumentality

Product Identification

• Zydus's ANDA Product, identified as generic zanubrutinib tablets, 160 mg, submitted to the FDA under ANDA No. 220921 Compl. ¶ 2

Functionality and Market Context

• The accused product is a generic version of the branded pharmaceutical BRUKINSA® tablets Compl. ¶ 32 It contains the active ingredient zanubrutinib and is intended for the treatment of various B-cell cancers, such as mantle cell lymphoma and chronic lymphocytic leukemia Compl. ¶ 31 Compl. ¶ 46 The complaint alleges Zydus is seeking FDA approval to commercially manufacture and sell this generic product prior to the expiration of the patents-in-suit Compl. ¶ 34

IV. Analysis of Infringement Allegations

The complaint includes a diagram of the chemical structure of zanubrutinib, referred to as "Compound 1," which is the active pharmaceutical ingredient in the accused product Compl. ¶ 48

U.S. Patent No. 10,927,117 Infringement Allegations

• Identified Points of Contention:
  • Evidentiary Question: The complaint's allegations regarding the product's crystalline structure are made "upon information and belief" (Compl. ¶ 49). A primary point of contention will be an evidentiary one: what is the actual solid-state form of the zanubrutinib in Zydus's ANDA product? Discovery will be required to determine if its XRPD pattern falls within the claimed ranges. The complaint notes that Plaintiff's access to Zydus's ANDA and product samples was subject to "unreasonably restrictive conditions" Compl. ¶ 36
  • Claim Scope Question: The construction of the term "crystalline form" and the scope of the range "±0.2°" will be central. A dispute may arise as to whether Zydus's product, which may contain impurities or a mixture of crystalline and amorphous material, meets the definitional threshold of the claimed "crystalline form."

U.S. Patent No. 11,591,340 Infringement Allegations

• Identified Points of Contention:
  • Technical and Labeling Question: Infringement of this method claim hinges on two key questions. First, does the proposed labeling for Zydus's product instruct or encourage its use for treating mantle cell lymphoma? Second, does the Zydus product being administered actually contain the specific crystalline form defined by the patent's XRPD peaks?
  • Validity Question: Zydus has filed a Paragraph IV certification asserting that the '340 patent is invalid Compl. ¶ 77 This raises the question of whether the claimed method of treatment, using this specific crystalline form, was anticipated by or obvious in light of the prior art at the time of the invention.

V. Key Claim Terms for Construction

• The Term: "crystalline form"

• Context and Importance: This term appears in the independent claims of both the '117 and '340 patents and is the foundation of the claimed invention. Its construction will determine the required degree of crystalline order and purity for a product to infringe. Practitioners may focus on this term because generic pharmaceutical products can sometimes be mixtures of crystalline and amorphous material, and the definition will be critical to determining if Zydus's product falls within the claim scope.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification consistently uses the phrase "a crystalline form," which may support an interpretation that does not require 100% purity, but rather the presence of a distinct, detectable crystalline solid state '117 Patent, abstract '117 Patent, col. 3:1-5
  • Evidence for a Narrower Interpretation: The patent explicitly distinguishes the invention from the "amorphous form," which it characterizes as having low stability and being hard to purify '117 Patent, col. 2:62-67 A defendant could argue this distinction implies the claimed "crystalline form" must be substantially pure and free of significant amorphous content to achieve the stated benefits.

• The Term: "treating"

• Context and Importance: This term is central to the method-of-use claims in the '340 patent and others. The scope of "treating" will be critical to the inducement analysis. Zydus's defense may involve arguing that its proposed product label, while potentially overlapping with the patent, does not induce infringement of the full scope of "treating" as construed from the patent.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The patent family includes patents that explicitly claim a "method for the delay of progression or treatment" (Compl. ¶ 195, discussing the '357 patent). Plaintiffs may argue this suggests "treating" in the '340 patent should be construed broadly to encompass not only arresting a disease but also slowing its progression. The specification also discusses inhibiting tumor growth in B-cell malignancies, which could support a broad interpretation '340 Patent, col. 2:40-42
  • Evidence for a Narrower Interpretation: A defendant may argue that the term "treating," when used alone, implies an action to cure or ameliorate existing symptoms, and might not extend to prophylactic use or merely slowing progression, particularly if other patents in the family use more specific language to cover those methods.

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement for the asserted patents. The inducement allegations are based on the assertion that Zydus's proposed product labeling will instruct physicians and patients to use the generic product in a manner that directly infringes the method-of-use claims Compl. ¶ 79 Compl. ¶ 93 The contributory infringement allegations are based on the assertion that Zydus's product is not a staple article of commerce and lacks substantial non-infringing uses Compl. ¶ 62 Compl. ¶ 94
• Willful Infringement: The complaint alleges that Zydus has acted with "full knowledge" of the patents-in-suit and "without a reasonable basis for believing that it would not be liable for infringement" Compl. ¶ 65 Compl. ¶ 97 This allegation of pre-suit knowledge is supported by Zydus's submission of Paragraph IV certifications to the FDA, which is an explicit acknowledgement of the existence of the patents covering BRUKINSA® Compl. ¶ 45 Compl. ¶ 77

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of physical characterization: Does the active pharmaceutical ingredient in Zydus's proposed generic product exist in the specific "Crystalline Form A" as defined by the X-ray diffraction patterns recited in the asserted claims, and what is the evidentiary burden for proving this composition?
• A key legal question will be one of induced infringement: To what extent will the final, FDA-approved labeling for Zydus's product explicitly direct or implicitly encourage medical professionals to prescribe and administer the drug in a manner that aligns with the specific treatment methods and dosing regimens claimed in patents such as the '340, '674, and '500 patents?
• A central dispute will be over patent validity: Can Zydus prove by clear and convincing evidence that the claims to a specific crystalline form of zanubrutinib, or methods of its use at particular doses, were obvious or anticipated by the prior art at the time of invention, as asserted in its Paragraph IV certifications?